RLBP1 — Retinaldehyde binding protein 1

The RLBP1 gene provides instructions for making a protein called cellular retinaldehyde-binding protein (CRALBP). This protein is essential for the "visual cycle," a process in the eye that recycles Vitamin A so that the light-sensing cells (photoreceptors) can continuously detect light. CRALBP acts like a shuttle, carrying specific forms of Vitamin A within the supportive cells of the retina. When the RLBP1 gene is mutated, the CRALBP protein doesn't work correctly or is missing. This disrupts the visual cycle, meaning the eye cannot efficiently recycle Vitamin A. As a result, the light-sensing cells slowly degenerate and die. For patients, this typically begins with night blindness and delayed dark adaptation in childhood, progressing to a loss of side (peripheral) vision and eventually central vision, leading to severe visual impairment. RLBP1-related retinal diseases are inherited in an autosomal recessive pattern. This means a person must inherit two mutated copies of the gene (one from each parent) to develop the condition. The parents, who each carry one mutated copy, typically do not have any symptoms. If both parents are carriers, there is a 25% chance with each pregnancy of having an affected child.

Gene description: Encodes cellular retinaldehyde-binding protein (CRALBP), essential for the visual cycle.

Patient and family guide: The RLBP1 gene provides instructions for making a protein called cellular retinaldehyde-binding protein (CRALBP). This protein is essential for the "visual cycle," a process in the eye that recycles Vitamin A so that the light-sensing cells (photoreceptors) can continuously detect light. CRALBP acts like a shuttle, carrying specific forms of Vitamin A within the supportive cells of the retina. When the RLBP1 gene is mutated, the CRALBP protein doesn't work correctly or is missing. This disrupts the visual cycle, meaning the eye cannot efficiently recycle Vitamin A. As a result, the light-sensing cells slowly degenerate and die. For patients, this typically begins with night blindness and delayed dark adaptation in childhood, progressing to a loss of side (peripheral) vision and eventually central vision, leading to severe visual impairment. RLBP1-related retinal diseases are inherited in an autosomal recessive pattern. This means a person must inherit two mutated copies of the gene (one from each parent) to develop the condition. The parents, who each carry one mutated copy, typically do not have any symptoms. If both parents are carriers, there is a 25% chance with each pregnancy of having an affected child.

Gene function: RLBP1 encodes CRALBP, a protein primarily expressed in the retinal pigment epithelium and Müller cells. It binds 11-cis-retinal and 11-cis-retinol, facilitating their transport and isomerization during the visual cycle, which regenerates the chromophore for rhodopsin and cone opsins.

Protein structure: The RLBP1 gene encodes the cellular retinaldehyde-binding protein (CRALBP), a 316-amino acid, 36-kDa water-soluble protein. It belongs to the CRAL-TRIO lipid-binding domain family. The protein's structure is characterized by a large hydrophobic cavity that serves as the binding pocket for its physiological ligands, 11-cis-retinol and 11-cis-retinaldehyde. The CRAL-TRIO domain is crucial for the protein's function, allowing it to encapsulate the hydrophobic retinoids and shield them from the aqueous cellular environment. Mutations in this domain, particularly those altering the shape or charge of the binding pocket, severely impair the protein's ability to bind and transport retinoids, leading to disease.

Molecular function: The RLBP1 gene encodes the cellular retinaldehyde-binding protein (CRALBP), a 36-kDa water-soluble protein that is a critical component of the visual cycle. CRALBP functions as a carrier protein for retinoids, specifically binding 11-cis-retinol and 11-cis-retinaldehyde with high affinity. In the retinal pigment epithelium (RPE) and Müller cells, CRALBP facilitates the enzymatic conversion of all-trans-retinoids back to the 11-cis-retinoids required for phototransduction. It acts as a substrate carrier, protecting these hydrophobic retinoids in the aqueous environment of the cytoplasm and presenting them to the enzymes of the visual cycle, such as 11-cis-retinol dehydrogenase. This process is essential for the regeneration of visual pigments (rhodopsin and cone opsins) after light exposure.

Expression pattern: The RLBP1 gene is predominantly expressed in the retina and the pineal gland. Within the retina, its expression is highly specific to the retinal pigment epithelium (RPE) and Müller glial cells. It is not expressed in the photoreceptor cells themselves. The protein is localized to the cytoplasm of these cells, where it plays a crucial role in the visual cycle. The high expression in Müller cells and RPE underscores the importance of these supporting cells in maintaining photoreceptor function and retinoid metabolism.

Mutation spectrum: The mutation spectrum of RLBP1 includes missense, nonsense, frameshift, and splice-site mutations. Over 20 pathogenic variants have been reported in the ClinVar database. Missense mutations often affect the retinoid-binding pocket of the CRALBP protein, impairing its ability to bind and transport 11-cis-retinoids. Founder mutations are a significant feature of RLBP1 genetics. The p.Arg234Trp mutation is a well-known founder mutation responsible for Bothnia retinal dystrophy in northern Sweden. Another founder effect is seen in Newfoundland rod-cone dystrophy, caused by specific splice-junction mutations. These founder mutations lead to a higher prevalence of the disease in these specific populations.

Pathogenic variants: 1. p.Arg234Trp (c.700C>T) - The classic founder mutation for Bothnia retinal dystrophy, leading to severe rod-cone dystrophy. 2. p.Arg150Gln (c.449G>A) - Associated with fundus albipunctatus and retinitis punctata albescens, sometimes with a milder or slower-progressing phenotype. 3. c.141+1G>A - A splice-site mutation associated with Newfoundland rod-cone dystrophy, causing early-onset severe retinal degeneration. 4. p.Met226Lys (c.677T>A) - A missense mutation reported in patients with retinitis punctata albescens, affecting the retinoid-binding domain. 5. p.Arg151Gln (c.452G>A) - Another missense mutation linked to retinal dystrophy, altering a conserved arginine residue.

Clinical significance: Mutations in the RLBP1 gene cause a spectrum of autosomal recessive inherited retinal diseases. The most well-known is Bothnia retinal dystrophy, characterized by night blindness from early childhood, retinitis punctata albescens (RPA) with characteristic white dots in the fundus, and progressive loss of visual acuity and visual fields. Other associated phenotypes include fundus albipunctatus and Newfoundland rod-cone dystrophy. The clinical severity can vary, but these conditions generally lead to severe visual impairment or legal blindness by middle age. Patients typically experience delayed dark adaptation and progressive macular degeneration. The disease is primarily restricted to the eye, with no significant systemic features reported.

Inheritance: Autosomal recessive

Chromosomal location: 15q26.1

Genotype-phenotype correlations: Genotype-phenotype correlations in RLBP1-associated diseases are complex but show some patterns. The p.Arg234Trp mutation is classically associated with Bothnia retinal dystrophy, a severe form of the disease prevalent in northern Sweden. Splice-site mutations, such as those causing Newfoundland rod-cone dystrophy, often lead to an early-onset and severe phenotype. Milder phenotypes, such as some cases of fundus albipunctatus, may be associated with missense mutations that partially retain CRALBP function, like p.Arg150Gln. However, the clinical presentation can vary even among individuals with the same mutations, suggesting that other genetic or environmental factors may influence disease severity and progression.

Research and therapeutic approaches: Currently, there are no FDA-approved treatments specifically for RLBP1-associated retinal dystrophies. Management is primarily supportive, including low vision aids and regular monitoring. However, significant progress is being made in the development of gene therapies for this condition. A notable investigational approach is AAV-mediated gene therapy, which aims to deliver a functional copy of the RLBP1 gene to the RPE and Müller cells. A Phase 1/2 clinical trial (NCT03374657) is currently evaluating the safety and efficacy of an AAV8-RLBP1 gene therapy vector (CPK850) in patients with RLBP1 mutations. Early interim results have shown promise in improving dark adaptation and resolving disease-related retinal deposits, suggesting that restoring the visual cycle is a viable therapeutic strategy. This approach follows the successful precedent set by Luxturna (voretigene neparvovec-rzyl), an approved gene therapy for another visual cycle defect caused by RPE65 mutations.

Diagnostic testing: Diagnostic testing for RLBP1-associated retinal dystrophies typically involves comprehensive genetic testing, often using targeted gene panels for inherited retinal diseases or whole exome sequencing (WES). These tests can identify pathogenic variants in the RLBP1 gene, confirming the clinical diagnosis. Genetic counseling is highly recommended for affected individuals and their families. Since RLBP1-related disorders are inherited in an autosomal recessive manner, parents of an affected individual are obligate carriers, and siblings have a 25% chance of being affected. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.

Animal models: Mouse models with Rlbp1 knockouts have been instrumental in understanding the gene's role in the visual cycle. These models demonstrate delayed dark adaptation and reduced levels of 11-cis-retinal, consistent with the biochemical function of CRALBP. They also show accumulation of retinyl esters in the RPE, mirroring the delayed visual cycle kinetics seen in human patients. Zebrafish models (rlbp1a mutants) have also been developed and recapitulate many features of human blinding diseases caused by RLBP1 mutations. These models show impaired cone vision and disturbed retinoid metabolism, providing a valuable tool for studying the disease mechanisms and testing potential therapies.

Population genetics: RLBP1-associated retinal dystrophies are generally rare globally, but they show significantly higher prevalence in specific populations due to founder effects. The most notable is the Bothnia region of northern Sweden, where the p.Arg234Trp mutation has a high carrier frequency, leading to a cluster of Bothnia retinal dystrophy cases. Similarly, a specific splice-site mutation is prevalent in Newfoundland, Canada, causing Newfoundland rod-cone dystrophy. In the general population, the carrier frequency for RLBP1 mutations is very low, as reflected in large population databases like gnomAD.

Selected references: 1. Burstedt MS, et al. Bothnia dystrophy caused by mutations in the cellular retinaldehyde-binding protein gene (RLBP1) on chromosome 15q26. Invest Ophthalmol Vis Sci. 1999. PMID: 10586929 2. Eichers ER, et al. Newfoundland rod-cone dystrophy, an early-onset retinal dystrophy, is caused by splice-junction mutations in RLBP1. Am J Hum Genet. 2002. PMID: 11868161 3. Kvanta A, et al. Interim safety and efficacy of gene therapy for RLBP1-associated inherited retinal dystrophy. Nat Commun. 2024. PMID: 39256350 4. Morimura H, et al. Mutations in the RPE65 and RLBP1 genes and consanguinity in families with retinitis punctata albescens. Am J Hum Genet. 1999. PMID: 10090895 5. Saari JC. Vitamin A metabolism in rod and cone visual cycles. Annu Rev Nutr. 2012. PMID: 22809104 6. Katsanis N, et al. Mutations in the RLBP1 gene associated with fundus albipunctatus in a consanguineous Pakistani family. Clin Genet. 2001. PMID: 11453974